Biogen Idec, Inc. (Massachusetts), Elan Corporation PLC Shares Fall on FDA Concerns

NEW YORK - Shares of biotechnology companies Biogen Idec Inc. and Elan Corp. fell Monday on concerns a Food and Drug Administration panel may recommend against approving Tysabri as a Crohn’s disease treatment.

MORE ON THIS TOPIC